Dexcom, Inc. Files 8-K on Security Holder Vote Matters
Ticker: DXCM · Form: 8-K · Filed: May 24, 2024 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: DXCM
TL;DR
DXCM filed an 8-K about a shareholder vote - details to follow.
AI Summary
On May 22, 2024, Dexcom, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific proposals or outcomes of any votes, but indicates that a shareholder meeting or vote is scheduled or has occurred.
Why It Matters
This filing signals that Dexcom is engaging in corporate governance processes, which may involve significant decisions affecting shareholders.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain information about financial performance or significant operational changes.
Key Players & Entities
- DEXCOM INC (company) — Registrant
- 0001093557-24-000101 (filing_id) — Accession Number
- May 22, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 6340 Sequence Drive, San Diego, CA 92121 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Dexcom, Inc.'s security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 22, 2024.
What is Dexcom, Inc.'s state of incorporation?
Dexcom, Inc. is incorporated in Delaware.
What is the principal executive office address for Dexcom, Inc.?
The principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.
What is the purpose of this Form 8-K filing for Dexcom, Inc.?
The purpose of the filing is to report the submission of matters to a vote of security holders.
Filing Stats: 804 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-05-24 16:12:45
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global
Filing Documents
- dxcm-20240522.htm (8-K) — 57KB
- dxcm-20240522_g1.jpg (GRAPHIC) — 108KB
- 0001093557-24-000101.txt ( ) — 428KB
- dxcm-20240522.xsd (EX-101.SCH) — 2KB
- dxcm-20240522_lab.xml (EX-101.LAB) — 21KB
- dxcm-20240522_pre.xml (EX-101.PRE) — 12KB
- dxcm-20240522_htm.xml (XML) — 3KB
07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. On May 22, 2024, DexCom, Inc. ("Dexcom" or the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the close of business on March 27, 2024, the record date for the Annual Meeting, there were 396,025,556 shares of Dexcom's common stock, $0.001 par value per share, outstanding and entitled to vote. 362,430,100 shares were present in person or represented by proxy at the Annual Meeting, which constituted a quorum for the transaction of business. The matters described below were voted on at the Annual Meeting and the final number of votes cast for or against, as well as the number of abstentions and broker non-votes, with respect to each matter are as indicated. Proposal 1: Election of Directors . Dexcom stockholders elected the following ten nominees to the Company's board of directors, each to serve until Dexcom's 2025 annual meeting of stockholders or until their earlier death, resignation or removal, as follows: Name Votes For Votes Against Abstentions Broker Non-Votes Kevin R. Sayer 319,796,865 19,758,443 2,554,271 20,320,521 Steven R. Altman 332,084,617 9,328,842 696,120 20,320,521 Nicholas Augustinos 317,396,722 23,609,243 1,103,614 20,320,521 Richard A. Collins 336,264,527 5,148,005 697,047 20,320,521 Karen Dahut 338,078,541 3,334,921 696,117 20,320,521 Rimma Driscoll 341,157,887 256,345 695,347 20,320,521 Mark G. Foletta 329,910,313 10,214,840 1,984,426 20,320,521 Bridgette P. Heller 331,230,639 10,175,357 703,583 20,320,521 Kyle Malady 336,252,174 5,157,403 700,002 20,320,521 Eric J. Topol, M.D. 333,860,551 7,555,244 693,784 20,320,521 Proposal 2: Ratification of Independent Registered Public Accounting Firm . Dexcom stockholders ratified the selection by the audit committee of the board of directors of Ernst & Young LLP as Dexcom's independent registered public accounting firm for the fiscal year ending December 31, 2024, as follows: Vo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ Jereme M. Sylvain Date: May 24, 2024 Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)